Prosight Management’s Albireo Pharma Inc ALBO Stock Holding History

Prosight Management’s Portfolio ALBO Stock Details ALBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-32,900	Closed	-$1.16M	–	58
2021 Q2	$1.16M	Buy	+32,900	New	+$1.07M	0.72%	31

Other funds holding ALBO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

GKIM

GW&K Investment Management Boston, Massachusetts $11.3B AUM 31.98% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Prosight Management's ALBO Position: Q1 2023 in Review

Prosight Management sold out of Albireo Pharma Inc (ALBO) in Q1 2023, closing a stake of 486,726 shares — an estimated $10.5M sold.

Prosight Management first reported a position in ALBO in Q3 2018 and held it in 18 quarters. The position peaked at $14.3M in Q1 2022. 3 funds tracked by Wall St. Rank hold ALBO as of Q1 2023.

Prosight Management reported no remaining Albireo Pharma Inc position as of Q1 2023 after selling out during the quarter.
Prosight Management sold 486,726 Albireo Pharma Inc shares in Q1 2023, an estimated $10.5M.
Prosight Management first reported a position in Albireo Pharma Inc in Q3 2018 and held it in 18 quarters.
Prosight Management's Albireo Pharma Inc position peaked at $14.3M in Q1 2022.
3 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q1 2023.

Based on Prosight Management's 13F filing for Q1 2023, filed 12 May 2023.